Antibody-drug conjugate · Cytotoxic, directed at CD22 · developed by ASTRAZENECA
AZD4512 is an antibody-drug conjugate that binds CD22, a B-lineage transmembrane phosphoglycoprotein expressed on mature and malignant B cells. After internalization and linker cleavage, it releases a DNA topoisomerase I inhibitor that causes DNA damage and apoptosis in tumor cells. It is being studied in B-cell non-Hodgkin lymphoma.
Summary written with AI from the sources listed at the end of this page.
B-cell Non-Hodgkin Lymphoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →